Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 1, 2025

InVivoPlus mouse IgG2a isotype control

RRID:AB_1107771
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0085, RRID:AB_1107771)

Antibody Information

URL: http://antibodyregistry.org/AB_1107771

Proper Citation: (Bio X Cell Cat# BE0085, RRID:AB_1107771)

Target Antigen: Unknown Specificity

Host Organism: mouse

Clonality: isotype control

Comments: Consolidation on 12/2021: AB_1107771, AB_2894740.

Antibody Name: InVivoPlus mouse IgG2a isotype control

Description: This isotype control targets Unknown Specificity

Clone ID: clone C1.18.4

Antibody ID: AB_1107771

Vendor: Bio X Cell

Catalog Number: BE0085

Alternative Catalog Numbers: BP0085-50MG, BE0085-25MG, BP0085-25MG, BP0085-5MG, BE0085-1MG, BE0085-50MG, BE0085-100MG, BP0085-100MG, BE0085-5MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T005242+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus mouse IgG2a isotype control.

No alerts have been found for InVivoPlus mouse IgG2a isotype control.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Cell reports, 43(8), 114536.

Pozniak J, et al. (2024) A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell, 187(1), 166.

Subramanian S, et al. (2024) Microbiota regulates neonatal disease tolerance to virus-evoked necrotizing enterocolitis by shaping the STAT1-NLRC5 axis in the intestinal epithelium. Cell host & microbe, 32(10), 1805.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer cell.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng. Immunity, 57(6), 1360.

Hayes BH, et al. (2024) Chromosomal instability induced in cancer can enhance macrophage-initiated immune responses that include anti-tumor IgG. eLife, 12.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Lim YJ, et al. (2024) MicroRNA-19b exacerbates systemic sclerosis through promoting Th9

cells. Cell reports, 43(8), 114565.

Lin CP, et al. (2024) Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. Cancer cell.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. Cancer cell.

Carey A, et al. (2024) Age-associated accumulation of B cells promotes macrophage inflammation and inhibits lipolysis in adipose tissue during sepsis. Cell reports, 43(3), 113967.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 42(6), 985.

Russick J, et al. (2024) Tumor stage-driven disruption of NK cell maturation in human and murine tumors. iScience, 27(11), 111233.

Ramachandran M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell, 41(6), 1134.

Ullah I, et al. (2023) The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell reports. Medicine, 4(1), 100893.

Sutton MS, et al. (2023) Vaccine elicitation and structural basis for antibody protection against alphaviruses. Cell, 186(12), 2672.

Zhang Y, et al. (2023) ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression. Cell reports, 42(6), 112654.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-? axis. Cell reports, 42(8), 112944.